Manuel Mitola

In this very important day #COPDDay I think we must play more attention to SMOKING CESSATION: please read this Surgeon General’s Report on tobacco-related health disparities in the United States. This report recognizes that while we’ve made remarkable progress reducing tobacco use in the past 60 years, that progress has not been even. Smoking remains the leading preventable cause of disease and death in the United States. Cigarette smoking and exposure to secondhand tobacco smoke cause nearly half a million deaths in the United States each year—nearly one in five of all deaths. https://lnkd.in/deq6Q7JE from Dr. Vivek Murthy Surgeon General's Report Società Italiana di Pneumologia Corsi e Congressi AIPO Ricerche Centers for Disease Control and Prevention

5

Today is the International Day for the Elimination of Violence against Women, an essential occasion to shed light on the burden of gender violence. As part of Angelini Industries and on a journey to raise awareness around brain and mental health with Angelini Pharma, I've decided to focus on a critical yet invisible impact of gender violence: its toll on mental health. Violence against women, in fact, deeply impacts mental health, doubling the risk of depression and increasing PTSD and suicide risk among survivors.  You can read the full article here: https://lnkd.in/diYgWtMT #NoExcuse #AngeliniPharma #EveryStepCloser #WithYouInMind

198

1 commento

Il tempo delle fragole Are We entering the strawberry era for physicians? #AI #strawberry #chatgpt #revolution #DoctorLanguageModel This is the final warning for those considering careers as physicians: AI is becoming so advanced that the demand for human doctors will significantly decrease, especially in roles involving standard diagnostics and routine treatments, which will be increasingly replaced by AI. This is underscored by the massive performance leap of OpenAI’s o-1 model, also known as the “Strawberry” model, which was released as a preview yesterday. The model performs exceptionally well on a specialized medical dataset (AgentClinic-MedQA), greatly outperforming GPT-4o. The rapid advancements in AI’s ability to process complex medical information, deliver accurate diagnoses, provide medical advice, and recommend treatments will only accelerate.

24

7 commenti

Humanism in Marketing: Responsible Leadership and the Human-to-Human Approach This book by Philip Kotler , Waldemar Pfoertsch , Fabio Ancarani and Ivan Ureta, PhD (KCL) as editors is now available at @Amazon India Here is the link😊👍↑

6

3 commenti

Readiness for the journey….

39

#thought on digitization in Parma Digital transformation in pharmaceutical companies is accelerating due to increasing demand for efficiency, innovation, and patient-centric solutions. Here's the current scenario regarding adaptation: 1. Adoption of Emerging Technologies AI and Machine Learning: Used for drug discovery, clinical trial optimization, and predictive analytics. Blockchain: Enhances supply chain transparency, improves traceability, and ensures data integrity IoT and Wearables: Enables real-time monitoring and remote patient management. Cloud Computing: Supports data sharing, collaboration, and scalability in research and operations. 2. Focus on Data Integration Consolidating data from multiple sources such as R&D, clinical trials, and sales to generate actionable insights. Increased use of data lakes and analytics platforms to ensure a seamless flow of information. 3. Regulatory Adaptation Adapting to evolving global regulations on digital tools, patient data privacy (e.g., GDPR, HIPAA), and AI usage. Accelerated approvals for digital therapeutics and telemedicine solutions. 4. Patient-Centric Innovations Digital solutions tailored for patients, such as mobile apps, telehealth, and virtual care platforms. Adoption of personalized medicine enabled by genomic and biometric data analysis. 5. Agile Clinical Trials Use of decentralized trials with digital tools, enabling remote monitoring and virtual site visits. AI-driven patient recruitment and retention strategies. 6. Smart Supply Chain Real-time tracking and predictive analytics for inventory management. Automated distribution processes and better demand forecasting. 7. Cultural Shift Leadership investing in digital training and fostering a culture of innovation. Collaboration between IT, R&D, and commercial teams to align digital goals with business strategies. Current Challenges: Resistance to change in traditional processes. High initial investment and infrastructure requirements. Ensuring cybersecurity and compliance. Opportunities to grab for betterment: Better patient outcomes through faster drug development and delivery. Enhanced operational efficiency and cost reduction. Market differentiation through innovative digital

1

🧬 Unlocking the Future of Pharma with AI! 🧫 Imagine a world where pharmaceutical breakthroughs happen at lightning speed, driven by the power of artificial intelligence. In August 2023, the Pharma AI Readiness Index by CB Insights revealed which companies were leading the charge in this AI revolution. Curious to know who was at the forefront? 🏆 𝗧𝗼𝗽 𝗣𝗲𝗿𝗳𝗼𝗿𝗺𝗲𝗿𝘀: Roche and Bayer were setting the pace, thanks to their significant investments in AI talent, innovation, and execution 💡 𝗞𝗲𝘆 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: 𝗧𝗮𝗹𝗲𝗻𝘁: Attracting and retaining top AI specialists is crucial. These companies are excelling in building strong AI teams. 𝗘𝘅𝗲𝗰𝘂𝘁𝗶𝗼𝗻: Bringing AI-powered products to market and deploying AI across corporate functions is a game-changer. 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: Patents, acquisitions, and deal-making activities highlight their commitment to AI advancements. 📈 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀: As AI continues to evolve, these companies are best positioned to harness its potential, driving innovation and improving patient outcomes. 🔗 𝗗𝗶𝘃𝗲 𝗗𝗲𝗲𝗽𝗲𝗿: Check out the full report to see how the top 50 pharmaceutical companies are preparing for an AI-driven future 👉 'Pharma AI Readiness Index: Who’s best-positioned for the AI boom?' - CB Insight https://lnkd.in/eWkVDuZV With so much to learn, the rapid evolution of AI in pharma and biotechnology is truly exciting. What are your thoughts on the future of AI in healthcare? #Pharma #AI #Innovation #Healthcare #FutureOfMedicine #CBInsights

7

Contact Inferre Consulting. We can support you to unlock your market potential! #marketresearch #gotomarket #productpositioning #marketingstrategy #businessgrowth #inferreconsulting #clientsuccess #collaboration #businessexpansion

4

1 commento

Managed entry agreements (MEAs) notionally saved the Italian healthcare system €220mn in 2022—an increase of 3.3% relative to 2022—according to new data from the Italian Medicines Agency (AIFA). However, it is important to bear in mind that savings are calculated relative to theoretical spending without MEAs, whereas prices would likely have been lower without MEAs. Several types of outcomes agreements are possible in Italy: 𝗥𝗶𝘀𝗸 𝘀𝗵𝗮𝗿𝗶𝗻𝗴 requires pharmaceutical companies to refund part of the treatment cost for non-responders. 𝗣𝗮𝘆𝗺𝗲𝗻𝘁 𝗯𝘆 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 (𝗣𝗯𝗥) requires manufacturers to repay in full the treatment cost for non-responders. PbR is used to manage a high degree of uncertainty for drugs that are perceived to have an unfavourable benefit/risk ratio at launch. Virtually all of the active outcomes agreements are PbR schemes. 𝗦𝘂𝗰𝗰𝗲𝘀𝘀 𝗳𝗲𝗲 deals involve payments only if outcomes targets are met. 𝗣𝗮𝘆𝗺𝗲𝗻𝘁 𝗮𝘁 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 (𝗣𝗮𝗥) is a variation on the success fee model, with staggered payments made if outcomes are met at specified timepoints. AIFA also operates two types of financial agreements: 𝗖𝗼𝘀𝘁 𝘀𝗵𝗮𝗿𝗶𝗻𝗴 provides for a discount on the cost of the first cycle of treatment, or the entire course of therapy, for all eligible patients. This type of deal is generally used in cases of uncertainty regarding the potential financial impact of a new medicine (as opposed to uncertainty regarding its effectiveness). 𝗖𝗮𝗽𝗽𝗶𝗻𝗴 sets a ceiling on expenditure on a drug per patient, beyond which the manufacturer covers all remaining costs. In addition to the patient-level MEAs managed through AIFA’s registries, Italy makes use of two population-level approaches to managed entry: 𝗣𝗿𝗼𝗱𝘂𝗰𝘁-𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗲𝘅𝗽𝗲𝗻𝗱𝗶𝘁𝘂𝗿𝗲 𝗰𝗲𝗶𝗹𝗶𝗻𝗴𝘀: AIFA negotiates a national limit for spending on a given drug in its first 12 or 24 months on the market. If this limit is exceeded, the manufacturer must refund excess costs to regional administrations. 𝗣𝗿𝗶𝗰𝗲-𝘃𝗼𝗹𝘂𝗺𝗲 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀 provide for incremental discounts on list prices in response to growing prescription volume. The discounts may be in the form of a price reduction or a refund to the regions. In 2023, AIFA had 5 PbR schemes (down from 10 in 2022), 3 PaR agreements (same as in 2022), 5 cost-sharing deals (down from 6 in 2022) and 7 capping arrangements in operation (same as in 2022). Expenditure ceilings were in place for 16 drugs (up from 12 in 2022), while 6 products were subject to price-volume agreements (up from 4 in 2022). The accompanying figure shows that notional savings from expenditure ceilings grew dramatically, whereas refunds from price-volume agreements, cost sharing, PbR, capping and risk sharing declined. PaR agreements are not included in the savings calculations because they provide for deferred billings over time rather than refunds. #Italy #managedentry #MEA #AIFA

233

1 commento

🙏 A huge shoutout to Marco Andre 🤖 for spotlighting my thoughts about the "The Future after the Future" and the role of AI for global marketing & digital leaders! ✔️ The future is now - let's experiment with AI to reshape our work today ✔️ Think of AI as your next-gen agency partner; prompts are the new creative briefs ✔️ Soft skills like agility and rapid learning are becoming increasingly vital 🌟 What are your thoughts on the "Future after the Future"? #AIinMarketing  #FutureofWork #PharmaChangemakers #DigitalTransformation #TevaNexter  

12

1 commento

Scientific #innovation is crucial in addressing global challenges such as global warming and food shortages. And to make the best use of the expertise, brilliant minds and ideas across organizations, research collaborations are essential to achieve scientific discoveries. 🔬 However, some view scientific partnerships, particularly between the public and private sector, with a degree of skepticism. In order to strengthen trust in #science, we at Bayer set up a public transparency register, the Bayer Science Collaboration Explorer, to provide #transparency about our science partnerships with universities, public research institutions, and individuals. Discover more at bayer.com/bsce. #TeamBayer

7

Navigating Marketing Mix Modeling (MMM) Without Bias Building an effective MMM requires carefully selecting variables to avoid biased channel estimates. This article presents a very detailed account of essential guidance on which variables to include—and which to leave out—for a model that truly reflects channel impact. A great read for anyone looking to fine-tune their media strategy and make data-driven decisions with confidence. Read more here: https://lnkd.in/g6mbkC2z Thank you Dibu Philip for sharing this earlier. And kudos to the author Felix Germaine. #MarketingMixModeling #DataDrivenMarketing #MarketingStrategy #Marketing #MarketingEffectiveness

5

🎉 Welcome Nova Insights to The Guide! 🎉 Learn more: https://lnkd.in/df4EKYsV Need a partner to humanize digital transformation in healthcare? Nova Insights brings the expertise you need for product value, market expansion, and user engagement. #DigitalTransformation #HealthcareInnovation #TechForGood Is your business listed in The Guide?

2

“Healthcare marketing: Strategies and behavioral marketing models for health” In today's competitive healthcare landscape, it's more important than ever for healthcare organizations to have a strong marketing strategy. This book, “Healthcare marketing: Strategies and behavioral marketing models for health”, provider a comprehensive overview of the latest marketing techniques and strategies that can be used to reach and engage physiciancs and patients. The book is written by a team of experts in healthcare marketing, and it covers a wide range of topics, including: 🫳Understanding consumer behavior in healthcare 🫳Developing effective marketing campaigns 🫳Using social media to reach patients 🫳Measuring the ROI of healthcare marketing campaigns The book is also packed with case studies and examples of how healthcare organizations are using behavioral marketing to achieve their goals. If you're looking for a comprehensive guide to healthcare marketing and behaviour, this book is a must-read. #healthcaremarketing #behavioralmarketing #healthcare BHAVE converting data into future Healthcare marketing: Strategie e modelli di marketing comportamentale per la salute https://amzn.eu/d/00A3cTdW

1

CX + AI is more than just UX and research, it is a new experience universe. A year ago, I shared my initial vision of how AI agents could transform CX in pharma by enabling machines to work together in practical ways. Today, we’re starting to see this idea take shape. While we’re not there yet, I expect early examples of machine collaboration in pharma by the end of 2025—not perfect, but impactful. How do you see this evolving? What challenges should we prepare for? #PharmaInnovation #CustomerExperience #FutureOfWork #AIinPharma #DigitalTransformation #HealthcareInnovation #AIandCX #AIAgents #AIApplications #PharmaLeaders #HealthTech #MedicalAI #EmergingTechnologies #LifeSciences https://lnkd.in/eirp6Gx9

28

3 commenti

Navigating the EU JCA & Local HTA Processes Just Got Simpler! Are you facing challenges with EU Joint Clinical Assessments (JCAs) and local HTA decision-making? 🌍 The evolving landscape of health technology assessments (HTAs) in Europe demands clarity and strategy. Our free eBook is here to guide you! 📖 What you’ll learn: ✅ Step-by-step strategies for navigating EU JCA submissions ✅ How to align with local HTA requirements seamlessly ✅ Insights to streamline your processes and improve decision-making Whether you’re in market access, regulatory affairs, or clinical development, this is a must-read! 📥 Download the eBook now and stay ahead: https://hubs.ly/Q02ZN5Gv0 #EUJCA #HTA #MarketAccess #Pharma #RegulatoryAffairs #HealthcareInnovation

6

#GenerativeAI experts! I want to learn and sharpen my #PromptEngineering skills for deeper #MarketInsights and better #QualitativeData analysis. If you know of any free courses, easy-to-follow learning paths, or certifications, please share in the comments. I’d love to learn from your recommendations! #AI #DataAnalysis #TechTrends #CareerGrowth #ProfessionalDevelopment #Learning #Innovation

7

1 commento